NASDAQ:APTX - Aptinyx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptinyx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.50 +0.06 (+1.35 %) (As of 01/27/2020 04:00 PM ET) Add Compare Today's Range$4.21Now: $4.50▼$4.5850-Day Range$3.15MA: $3.85▼$5.0352-Week Range$2.61Now: $4.50▼$6.00Volume294,385 shsAverage Volume593,634 shsMarket Capitalization$197.31 millionP/E RatioN/ADividend YieldN/ABeta0.19 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.aptinyx.com/ Phone847-871-0377Debt Debt-to-Equity RatioN/A Current Ratio16.75 Quick Ratio16.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.57 million Price / Sales30.03 Cash FlowN/A Price / Cash FlowN/A Book Value$4.46 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)($2.64) Net Income$-53,280,000.00 Net Margins-1,523.09% Return on Equity-44.24% Return on Assets-42.20%Miscellaneous EmployeesN/A Outstanding Shares43,846,000Market Cap$197.31 million Next Earnings Date3/19/2020 (Estimated) OptionableNot Optionable Receive APTX News and Ratings via Email Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:APTX Rates by TradingView Aptinyx (NASDAQ:APTX) Frequently Asked Questions What is Aptinyx's stock symbol? Aptinyx trades on the NASDAQ under the ticker symbol "APTX." How were Aptinyx's earnings last quarter? Aptinyx Inc (NASDAQ:APTX) issued its earnings results on Tuesday, November, 12th. The company reported ($0.44) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.44). The firm earned $0.94 million during the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative net margin of 1,523.09% and a negative return on equity of 44.24%. View Aptinyx's Earnings History. When is Aptinyx's next earnings date? Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx. What price target have analysts set for APTX? 6 analysts have issued twelve-month price targets for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's stock price to reach $10.33 in the next year. This suggests a possible upside of 129.6% from the stock's current price. View Analyst Price Targets for Aptinyx. What is the consensus analysts' recommendation for Aptinyx? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx. What are Wall Street analysts saying about Aptinyx stock? Here are some recent quotes from research analysts about Aptinyx stock: 1. According to Zacks Investment Research, "Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. " (1/22/2020) 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $12 on APTX. With an initial focus on large indications within chronic pain, there are multiple nervous system disorder opptys for the company’s candidates that have a better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models look promising, and important PoC trial data should emerge this year. Valuation Summary We use a discounted NPV revenue calculation that yields ~$10 for NYX-2925 in DPN and ~$2 for pipeline placeholder ($75M total NPV) in fibromyalgia." (4/30/2019) Has Aptinyx been receiving favorable news coverage? News coverage about APTX stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptinyx earned a news impact score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aptinyx. Are investors shorting Aptinyx? Aptinyx saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 169,500 shares, a drop of 70.4% from the December 31st total of 572,800 shares. Based on an average daily volume of 146,800 shares, the short-interest ratio is presently 1.2 days. Currently, 1.1% of the company's shares are sold short. View Aptinyx's Current Options Chain. Who are some of Aptinyx's key competitors? Some companies that are related to Aptinyx include Eagle Pharmaceuticals (EGRX), Stoke Therapeutics (STOK), CannTrust (CNTTF), Vanda Pharmaceuticals (VNDA), Provention Bio (PRVB), ANI Pharmaceuticals (ANIP), Emisphere Technologies (EMIS), Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), Akero Therapeutics (AKRO), Collegium Pharmaceutical (COLL), Retrophin (RTRX), Frequency Therapeutics (FREQ), Homology Medicines (FIXX) and Omeros (OMER). What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), vTv Therapeutics (VTVT), Canopy Growth (CGC), Inseego (INSG), Corbus Pharmaceuticals (CRBP), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX), Virgin Galactic (SPCE) and VBI Vaccines (VBIV). Who are Aptinyx's key executives? Aptinyx's management team includes the folowing people: Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)Ms. Betty Y. Jang, VP of Legal Affairs (Age 50) When did Aptinyx IPO? (APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. How do I buy shares of Aptinyx? Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aptinyx's stock price today? One share of APTX stock can currently be purchased for approximately $4.50. How big of a company is Aptinyx? Aptinyx has a market capitalization of $197.31 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx. What is Aptinyx's official website? The official website for Aptinyx is http://www.aptinyx.com/. How can I contact Aptinyx? Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected] MarketBeat Community Rating for Aptinyx (NASDAQ APTX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 95 (Vote Outperform)Underperform Votes: 89 (Vote Underperform)Total Votes: 184MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is the price-sales ratio?
